Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 25, Pages 6535-6543
Publisher
American Society of Hematology
Online
2011-10-13
DOI
10.1182/blood-2011-05-354530
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
- (2011) G. Avvisati et al. BLOOD
- Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia
- (2011) Ardeshir Ghavamzadeh et al. JOURNAL OF CLINICAL ONCOLOGY
- Modern Approaches to Treating Acute Promyelocytic Leukemia
- (2011) Miguel A. Sanz et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
- (2010) M. A. Sanz et al. BLOOD
- Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia
- (2010) J. Imagawa et al. BLOOD
- Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
- (2010) F. Lo-Coco et al. BLOOD
- Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
- (2010) B. L. Powell et al. BLOOD
- Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
- (2010) P. Montesinos et al. BLOOD
- Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia
- (2010) Steven D. Gore et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemotherapy
- (2010) Pau Montesinos et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data
- (2010) Vikram Mathews et al. JOURNAL OF CLINICAL ONCOLOGY
- How I treat acute promyelocytic leukemia
- (2009) M. S. Tallman et al. BLOOD
- Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience
- (2009) Charikleia Kelaidi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
- (2009) David Grimwade et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
- (2008) M. A. Sanz et al. BLOOD
- Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
- (2008) M. A. Sanz et al. BLOOD
- Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
- (2008) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More